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 Abstract 
“Candidatus Neoehrlichia mikurensis” (Ca. N. mikurensis) is a tick-borne bacterial 
pathogen that can cause disease particularly among immune compromised persons. 
This new infectious disease is called neoehrlichiosis.  The clinical picture of neoehr-
lichios is characterized by fever, migrating pain, and vascular/thromboembolic 
complications. The bacterium received its name in 2004, after its discovery in ticks 
and rodents on the Japanese island of Mikura. This thesis have four main aims 1) Map 
this new infectious disease with respect to what types of patients that are afflicted, the 
clinical picture displayed by the patient categories, and the pattern of laboratory 
findings seen in infected patients. This is described in paper I; where clinical data of 
six patients participating in the “NEO-VÄST study” are described together with 
additional cases from Europe. 2) Determine if Ca. N. mikurensis is an opportunist that 
only afflicts immune compromised patients? In paper II we describe two immune 
competent patients who had raised levels of Ca. N. mikurensis DNA in the blood 
accompanied by a cytokine response for several months. The patients were diagnosed 
after PCR screening of plasma samples from 102 tick-bitten persons in Sweden who 
participated in the Tick-Borne Disease Study called STING. A PCR assay for clinical 
use was developed in this study and the cytokine levels were measured with multiplex 
technology. 3) Establish if Ca. N. mikurensis strains in Europe vary genetically. Paper 
III describes the development and use of a multilocus sequence analysis (MLSA) 
protocol to investigate the genetic diversity of clinical Ca. N. mikurensis strains in 
Europe. A low genetic diversity was seen among the strains, all of which were derived 
from immune compromised patients. Unexpectedly, Ehrlichia ruminantium was found 
to be the closest relative of Ca. N. mikurensis within the family of Anaplasmataceae. 
4) Perform de novo whole-genome sequencing of Ca. N. mikurensis to characterize 
the bacterium. In paper IV we determined the complete reference genome sequence of 
Ca. N. mikurensis, sequenced directly from the blood of three immune suppressed 
patients. We also compared these sequences with those of other whole-genome 
sequenced relatives of Ca. N. mikurensis. The sequencing strategy relied on library 
preparation using a new type of technology called 10X Chromium followed by Hiseq 
Illumina sequencing, sequence assembly and de novo annotation. Our studies have 
yielded more knowledge about this anonymous emerging pathogen but much remains 
to be resolved, the work continues! 
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 Sammanfattning på svenska 
Candidatus Neoehrlichia mikurensis (Ca. N. mikurensis) är en fästingburen bakterie 
som kan orsaka sjukdom hos människa. Det är främst patienter med nedsatt immunför-
svar som drabbas av denna nya infektionssjukdom som kallas ”neoehrlichios”. Sym-
tombilden vid neoehrlichios kan se väldigt olika ut men de vanligaste kännetecknen är 
feber, migrerande muskelvärk, huvudvärk, nackstelhet och ledvärk. De allvarligaste 
konsekvenserna av infektionen är de tromboemboliska och vaskulära komplikationer 
som över hälften av svenska patienter har drabbats utav. De första fallen av neoehrli-
chios hos människa publicerades 2010 men bakterien namngavs redan 2004 då den 
hittades hos fästingar och råttor på ön Mikura i Japan. Denna avhandling innehåller fyra 
delarbeten där det huvudsakliga målet har varit att ta reda på mer om denna infektions-
sjukdom samt förbättra diagnostiken så att flera patienter kan identifieras, behandlas, 
slippa långvarigt lidande och svåra komplikationer. I det första arbetet beskrivs symp-
tom och fynd hos svenska, tyska, schweiziska och tjeckiska patienter som hade diagnos-
tiserats med neoehrlichios och vars fallrapporter publicerats fram till 2013. I delarbete II 
undersöks om Ca. N. mikurensis kan ge upphov till sjukdom hos patienter med normalt 
immunförsvar. Mikrobiologisk diagnostik i form av en PCR (polymeras chain reaction) 
specifik för Ca. N. mikurensis sattes upp för analys av blodprov från friska människor 
som blivit bitna av fästingar, ingått i fästingstudien STING och därefter utvecklat 
symtom. Två patienter diagnostiserades med Ca. N. mikurensis och beskrivs. Delarbete 
III fokuserar på att med hjälp av nyuppsatt epidemiologisk typningsmetod jämföra olika 
europeiska kliniska stammar av Ca. N. mikurensis för att se om dessa är genetiskt lika 
varandra och få en bättre uppfattning om släktskapet till övriga medlemmar i bakterie-
familjen Anaplasmataceae. Vi fann att isolaten var väldigt lika varandra och skiljdes åt 
avseende ett fåtal nukleotider. Ehrlichia ruminantium som orsakar svår sjukdom hos 
boskap beskrivs här som Ca. N. mikurensis närmaste släkting. I delarbete IV använder 
vi oss av ny sekvenseringsteknik för att helgenomsekvensera denna bakterie direkt från 
blod taget från patienter diagnostiserade med neoehrlichios. Detta lyckas och vi beskri-
ver storleken på genomet hos Ca. N. mikurensis som är ca 1.1 Mb och vi finner även att 
de tre sekvenserade isolaten från de svenska patienterna är väldigt lika. Våra studier har 
redan hjälpt flera patienter men det finns fortfarande mycket att lära sig om denna nya 
infektionssjukdom. Arbetet fortsätter och förhoppningsvis kommer våra resultat att 
ledatill ännu bättre diagnostiska möjligheter för dessa patienter och en ökad kunskap om 
Ca.N.mikurensis!  
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Abbreviations 
Ank Ankyrin protein 
Ca. N. mikurensis Candidatus Neoehrlichia mikurensis 
CDS Coding sequence 
CLL Chronic lymphocytic leukemia 
ClpB Caseinolytic Peptidase B 
CSF  Cerebrospinal fluid 
CT Cycle threshold 
CTL  Cytotoxtic T-lymphocytes 
CRP  C-reactive protein 
DC Denditric cell 
DLCBL  Diffuse large B-cell lymphoma 
DNA  Deoxyribonucleic acid 
DNTP Deoxynucleotide 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EM Erythema migrans 
EMLA Ehrlichia muris-like agent 
FAM Fluorescein 
FtsZ Filamenting temperature-sensitive mutant Z 
GEM Gel bead in Emulsion 
HGA Human granulocytic anaplasmosis 
HME Human monocytic ehrlichiosis 
HMW High molecular weight 
IFA Immunofluorescence assay 
IL Interleukin 
INF Interferon 
IRE Ixodes ricinus 
ISE  Ixodes scapularis 
LGL Large granular lymphocyte leukemia 
LPS Lipopolysaccharides 
LipA  Lipase A 
Mb Mega base 
MIP Major intrinsic protein 
MLSA Multilocus sequence assay 
MLST Multilocus sequence typing 
NGS Next generation sequencing 
NO Nitric oxide 
NK Natural killer 
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OMP Outer membrane protein 
PTLD Post-transplant lymphoproliferative disorder 
PAMPS  Pathogen-associated molecular pattern 
PE Phycoerythrin 
PCR Polymerase chain reaction 
RNA  Ribonucleic acid 
ROS Reactive oxygen species 
SLE Systemic lupus erythematosus 
SNV Single-nucleotide variants 
TBE Tick-borne encephalitis 
TBD Tick-Borne Diseases 
T4SS Type IV secretion system 
TNF Tumor necrosis factor 
UPGMA Unweighted pair group method with arithmetic mean 
VEGF Vascular endothelial growth factor 
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Introduction 
Ticks  
Ticks are external parasites that live by feeding on the blood of 
mammals, birds and reptiles. They are widely distributed over the 
world and they even existed at the age of the dinosaurs
1
. There are 
two major families of ticks, the Ixodidae, or hard ticks, and the Ar-
gasidae, or soft ticks. Hard ticks consist of a hard shield that covers 
the dorsal region and they have a head with mouth and feeding 
parts in the front whereas soft ticks have their mouthparts on the 
underside of the body. In Europe, Ixodid ticks, and Ixodes ricinus  
  
Figure 1 Tick life cycle 
An adult female tick lays up to 3,000 eggs. When the larvae emerge, they feed 
and after feeding, they detach from their host and moult to nymphs in the vegeta-
tion. During moulting the tick sheds the previous skin or shell. The nymphs then 
feed on larger hosts and moult to adults. Female adults attach to larger hosts, 
feed and copulate with an adult male and after that, lay eggs. Males do not need 
to feed but occupy larger hosts primarily for mating. This life cycle can take be-
tween two to three years depending on climate. 
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in particular, are important vectors of human and animal parasitic, 
bacterial and viral pathogens
2
. Ticks of the genus Ixodes find their 
host using the sensory organs on their front legs (Haller´s organ). 
These organs can sense carbon dioxide, temperature, odors and 
movement, all of which signal the appearance of a blood-filled 
host
3
. 
 
In Sweden, the most common hard tick is Ixodes ricinus. This tick 
species has a three-host life cycle; it depends on three vertebrate 
hosts for blood meals (Figure 1). I. ricinus is able to take advantage 
of a multitude of host species, which differ with respect to the 
number of ticks and the different life stages they feed
4
. Larvae and 
nymphs mainly feed on small rodents and birds whereas adults 
feed on multiple host species, often roe deer, Capreolus capreo-
lus
5
. 
 
In Europe, the Ixodes tick is found primarily in woodlands with a 
permanent layer of leaves and bushes that protect them from sun-
light. This is the preferred microhabitat of the off-host phases, 
characterized by relative humidity, which should not go below 
80% for the survival of the ticks. There, all developmental stages 
(unfed as well as engorged ticks) are able to survive winter
6
.The 
ticks become active when the temperature exceeds 4-5˚C, i.e. they 
start to quest for hosts. The ticks can quest for several months if 
there is a suitable habitat, but they must replenish their reserves of 
water by frequent journeys from the surface vegetation down to the 
base layer of the vegetation
7
. In northern Europe, the peak of quest-
ing adult and nymphal ticks usually occurs in spring and early 
summer
7
. Low-level activity takes place during mid-summer alt-
hough questing may persist throughout the summer in cool and 
humid conditions, especially in relatively protected habitats. In 
many areas, a second peak of activity occurs in autumn. Larval 
ticks typically begin questing slightly later than the adults and 
nymphs, appearing in large numbers in early summer and reaching 
their highest activity peaks in mid-summer. I. ricinus seasonal ac-
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tivity is controlled by a biological strategy where ticks avoid quest-
ing at unfavorable times of the year. In that way they can increase 
their survival by responding to current conditions
7
. 
Tick-borne infections 
During the last decades the emergence of tick-borne infections has 
increased remarkably in Europe
8
. This may be in part the result of 
advances in molecular biology since several new Rickettsial dis-
eases, Ehrlichial diseases, and novel agents of Borrelia and Babe-
sia genera have been recognized with the development of new 
diagnostic tools. The emergence of vector borne infectious diseases 
is a growing health concern for humans and livestock
8
 since the 
most common zoonotic vector are the ticks, and in Europe the main 
vector is Ixodes ricinus.  
 
The geographic distribution of ticks continues to expand and cli-
mate change is one reason for the spread of Ixodes ticks
9
. Some of 
the pathogens transmitted by the Ixodes ricinus tick include Borre-
lia burgdoferi sensu lato complex causing borreliosis, Anaplasma 
phagocytophilum causing human granulocytic anaplasmosis, 
Fransicella tularensis causing tularaemia, Rickettsia helvetica 
causing spotted fever rickettsiosis, Babesia divergens and Babesia 
microti responsible for babesiosis, Candidatus Neoehrlichia 
mikuensis causing neoehrlichiosis and tick-borne encephalitis virus 
(TBE)
9
. Althought the primary vector for ehrlichiosis is Amblyom-
ma americanum, Ixodes ticks can also transmit Ehrlichial species 
10
 
(Table 1). 
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Borreliosis 
In this thesis I have chosen to remove “Lyme” from Borreliosis 
since Lyme disease is caused by Borrelia burgdorferi sensu stricto 
in North America, whereas species belonging to the Borrelia 
burgdorferi sensu lato complex prevail in Europe. Consequently, 
the clinical manifestations described for Lyme disease differ from 
those characteristic of Borreliosis in Europe and in Asia. 
 
Borreliosis can affect several parts of the human body and is the 
most common tick-borne disease in the northern hemisphere. The 
Table 1 Tick-borne infections pose a threat to public health around the world, and they 
seem to be on the rise. 
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earliest symptom is the red skin lesion called erythema migrans 
(EM). EM can be visualized days to weeks after a tick bite and can 
enlarge from the site of the tick bite. Patients can experience flu-
like symptoms and the diagnosis is most often clinical since the 
patients are usually seronegative for Borrelia at this stage 
11
.  
 
After EM, neuroborreliosis is the second most common manifesta-
tion of disease in Sweden
12
. It appears 4-6 weeks after the tick bite 
with neurological symptoms such as facial palsy, nerve root pain, 
headache and fever. The diagnosis is based on medical history, 
clinical symptoms and serological analysis of serum and cerebro-
spinal fluid (CSF)
11
. 
 
Later manifestations of Borreliosis include arthritis that is charac-
terized by inflammation of large joints, and this condition causes a 
significant proportion of arthritis cases in children
13
. Acrodermati-
tis, a slow growing chronic skin condition that is most commonly 
seen on hands and feet in people older than 40 years. This condi-
tion almost only occurs in Europe
14
. Lymphocytoma,  a rare skin 
manifestation of Borreliosis, which can appear in the same area as 
a previous EM. Finally, carditis, which is a treatable condition of 
the heart and the least common manifestation of borreliosis in 
Sweden
12
. 
Anaplasmosis 
Anaplasma phagocytophilum causes human granulocytic anaplas-
mosis (HGA) and in Europe, the tick Ixodes ricinus is identified as 
the main vector transmitting the disease. The target cells of the 
bacteria are the neutrophils and the seroprevalence of A. phago-
cytophilum is between 5.7-8.1% in European populations 
15
 and 8-
21% in Sweden
16,17,18,19
. Despite the high seroprevalence of Ana-
plasma phagocytophilum antibodies in Sweden there are few case 
reports of anaplasmosis in Scandinavia
20
. In northern Europe, A. 
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phagocytophilum is more commonly the cause of tick-borne fever 
in domestic ruminants, horses and dogs
21
. The bacterium infects 
the cytoplasm of circulating neutrophils, seen as intracellular inclu-
sions known as morulae (microcolonies)
22
. Morulae can be detect-
ed in blood smears during acute febrile episodes. However, in 
Europe, morulae are a rare finding and symptomatic HGA infec-
tions are rarely diagnosed
23
. It is speculated that the European A. 
phagocytophilum strains are less virulent compared to the strains 
circulating in the USA
22,23
. The general clinical features of HGA 
are febrile illness with headache, myalgia and malaise accompa-
nied by leukopenia, thrombocytopenia and elevated levels of hepat-
ic enzymes
10
. The symptoms are generally mild to moderate, and 
subclinical infections occur. However, life-threatening complica-
tions have been reported in immune compromised individuals
19
. 
Today’s diagnostic tool for HGA is serology using an indirect fluo-
rescent antibody method (IFA) but PCR of peripheral blood is also 
possible
24
. 
Ehrlichiosis 
Human monocytic ehrlichiosis (HME) is mainly caused by Ehr-
lichia chaffeensis and the primary tick-vector for HME is the Lone 
Star tick, Amblyomma americanum. Following transmission via a 
tick bite, E. chaffeensis enters and multiplies within monocytes or 
macrophages forming intracellular microcolonies (morulae). So 
far, there are no reported cases of HME outside of the USA
25
. The 
average incidence of HME in the USA is estimated to 0.7 cas-
es/million population but can be much higher in endemic areas
10
. 
HME is a more severe disease than HGA and can be fatal even in 
immune competent patients, almost 50% of the cases require hospi-
talization
10
. Common symptoms are fever, headaches and myalgia. 
Gastrointestinal symptoms have been reported, mainly in children. 
Life-threatening manifestations include cardiovascular failure, 
haemorrhages, hepatic failure and respiratory distress syndrome.  
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HME can cause neurological manifestations such as meningitides 
but morulae are rarely identified in CSF monocytes
10,26
. A diagno-
sis of HME can be confirmed in several ways. Laboratory tests in-
clude serology, detection of morulae in blood smears, and 
detection of Ehrlichial DNA by PCR of blood or CSF samples. 
 
Ehrlichia ewingii and Ehrlichia canis were believed to be exclu-
sively canine pathogens until human cases of infection were de-
scribed
27,28
. Most human cases of E. ewingii infection (HEE) have 
occurred among immune suppressed patients and the bacteria may 
be visualized as morulae in granulocytes and the clinical manifes-
tations appear to be milder than HME 
27
. Ehrlichia canis is trans-
ferred most commonly between dogs by Rhipicephalus sanguineus, 
the brown dog tick that rarely bites humans
29
. But, since the human 
cases of E. canis have been reported from Venezuela, which is a 
tropical country with high rates of E. canis infections among dogs, 
it is surmised that the human infections are also transmitted by a 
bite of R.sanguineus
28
.   
 
Recently, a new member of the genus Ehrlichia was reported to 
cause human infection, an Ehrlichia muris-like agent (EMLA). It is 
transmitted by Ixodes scapularis and the cases were from the 
northern part of the USA. All patients were immune suppressed 
and had fever, fatigue, and headache as the main symptoms
30
.  
Spotted fevers 
The term Tick-borne Spotted Fevers is a catch-all term used to de-
scribe illnesses caused by ticks infected with Rickettsia bacteria. 
The most common forms of spotted fevers are African tick bite fe-
ver caused by R. africae, Mediterranean spotted fever caused by R. 
conorii, and the most severe form of them all is Rocky Mountain 
spotted fever
31
, caused by Rickettsia rickettsia, primarily transmit-
ted by the Dermacentor variabilis tick. Typically, symptoms of 
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Rocky Mountain spotted fever include a severe headache, chills, 
extreme exhaustion and muscle pains. Symptoms begin suddenly 3 
to 12 days after a tick bite and on the first days of fever, a rash ap-
pears on the wrists, palms, ankles, soles, and forearms. It rapidly 
extends to the neck, face, armpits, buttocks, and trunk.  These rash-
es are due to the bacterium infecting and multiplying within vascu-
lar endothelial cells, causing vasculitis of small to medium-sized 
blood vessels
32
. Spotted fever group rickettsiosis includes a large 
number of species, of which 24 are recognized human pathogens
33
.  
 
In Sweden and Denmark, where the most common tick species is 
Ixodes ricinus, Rickettsia helvetica is the dominant Rickettsial spe-
cies with a variable seroprevalence of 1.7–17.3 % 34,35. Despite this 
rather high prevalence, no significant difference were shown in the 
seroprevalence of antibodies against spotted fever Rickettsia be-
tween patients investigated for neuroborreliosis and healthy blood 
donors in a recent Danish study
35
. Case reports from Sweden sug-
gests that infection with R. helvetica may be involved in both sar-
coidosis and in chronic perimyocarditis with sudden cardiac death 
in two young men 
36,37
. There are also several reports of severe 
cases with neurological manifestations and meningitides caused by 
R. helvetica and R. felis 
38-40
. 
Tick-borne relapsing fever 
Tick-borne relapsing fever is characterized by recurring febrile epi-
sodes that last up to 3 days and are separated by afebrile periods of 
several days. Along with fever, patients may experience a wide 
range of nonspecific symptoms (e.g., headache, myalgia, arthralgia, 
shaking chills, and abdominal complaints). Neurological symptoms 
are common during relapsing fever and the most common symp-
toms are meningitis and facial palsy. Patients who are not treated 
with antibiotics typically experience several episodes of fever be-
fore illness resolves
41
. The illness in Europe is caused by infection 
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with Borrelia species that mainly are transmitted by Ornithodoros 
soft ticks (e.g., B. hispanica, B. persica and B. caucasica)
42
. Re-
cently, it has been discovered that human agents of relapsing fever 
may also be vectored by Ixodid ticks, chiefly the emerging patho-
gen Borrelia miyamotoi
43
. Human infection with B. miyamotoi has 
been reported from Russia, North America and Japan but in recent 
years cases from Europe have started to show up
44-46
: The first case 
was an elderly immune competent woman who sought medical 
care 3 weeks after a tick-bite because of fever, myalgia, headache, 
weight loss and an erythematous skin lesion
45
. The patient recov-
ered fully without antibiotic treatment. Another two cases with se-
vere manifestations, notably meningoencephalitis afflicting highly 
immune compromised patients from Germany and Netherlands 
have also been reported
44,46
. There are so far three reported case of 
meningoencephalitis caused by B. miyamotoi in the world
42
. 
Tick-borne tularaemia 
Tularaemia is caused by infection with the facultative intracellular, 
gram-negative bacterium Francisella tularensis and has been rec-
ognized as a human pathogen since the beginning of the 20th cen-
tury
47
. Humans can acquire this infection through several routes 
where tick bite is one of them. It can also be spread to humans by 
mosquitoes, contact with an infected animal, by drinking contami-
nated water, breathing contaminated dirt, or aerosol
48,49
. In Europe, 
the ticks Dermacentor reticularis and Ixodes ricinus are vectors for 
the bacterium, but in Sweden mosquitoes are considered to be the 
major transmitter of the bacteria
50
.  
 
The most common form of the disease in Sweden is ulceroglandu-
lar tularaemia, which is characterized by a skin ulcer at the site of 
infection and adjacent swollen regional lymph nodes and fever
51
. 
The mean incubation time is 3–5 days with a range of 1–21 days48. 
In some cases complications like soft tissue abscesses, pneumonia 
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and meningitis can occur
48
. The laboratory diagnosis is often based 
on the detection of specific serum antibodies and/or PCR for F. tu-
larensis DNA in clinical samples. The bacterium can disseminate 
easily and is classified as a Category A critical biological agent and 
the risk of laboratory-associated infections is high
52
.  
 
The family Anaplasmataceae 
The family Anaplasmataceae (Figure 2) belongs to the order Rick-
ettsiales together with the family Rickettsiaceae. All bacterial spe-
cies in the Anaplasmataceae family are obligate intracellular 
Figure 2 The family Anaplasmataceae 
A map over the family Anaplasmataceae; the headings indicate genera and the 
species coloured in red are human pathogens. Anaplasma, Ehrlichia and Candi-
datus Neoehrlichia are mainly transmitted by different species of ticks. Neorick-
ettsia are transmitted to mammals by eating infected fish or aquatic insects. 
Wolbachia infect arthropod species but have a role in the human infection lym-
phatic filariasis. 
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bacteria that infect invertebrates (pathogenic or non-pathogenic) 
but some species also infect mammals and birds. It has been pro-
posed that one major difference between Anaplasmataceae and 
Rickettsiaceae are that the bacteria belonging to Anaplasmataceae 
are enclosed within membrane-bound compartments in the host 
cytoplasm in contrast to the Rickettsiasceae that are free in the cy-
toplasm 
53,54
. Different stages of bacterial development have been 
suggested for Anaplasmataceae based on the reorganization of the 
bacterial DNA from an infectious form (dense-core) to a vegetative 
form (reticulate cell). The reticulate forms multiply by binary fis-
sion and form morulae and turn into dense-cored cells before being 
released from the host cell
54
 (Figure 3).  
 
 
 
 
Figure 3 Intracellular life cycle of Anaplasmataceae 
Dense-cored cells enter host cells and develop to replicating reticulate 
cells (vegetative form). A cluster of reticulate cells forms “morulae” 
that develop into mature dense-cored cells before being released by 
host cell rupture or exocytosis. Picture adapted from Pruneau et. 
al.[52] 
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Bacterial genera 
Neorickettsia  
Many species within the Anaplasmataceae family were known as 
veterinary pathogens before they were shown to infect humans. 
The first reported case of human infection by a bacterium belong-
ing to the family Anaplasmataceae was in 1954
55
. Neorickettsia 
sennetsu caused infectious mononucleosis in a patient in Japan and 
the route of human infection was thought to be the consumption of 
raw fish
55
. In recent years, human cases of N. sennetsu infection 
have been identified in both Thailand and Laos by PCR and serol-
ogy
55,56
.  All Neorickettsia spp. are thought to be transmitted by 
parasitic flatworms, which transmit the organisms to an animal or 
human host. No other species in the genus have been documented 
to cause infection in humans but N. helminthoeca can cause salmon 
poisoning disease in dogs and N. risticii is the cause of Potomac 
horse fever
57,58
.  
Wolbachia 
The genus Wolbachia was named by Hertig in 1936 and described 
as gram‐negative, intracellular, Rickettsiae‐like bacteria concen-
trated in the germline and somatic tissues of a broad range of in-
sects and other arthropods
59,60
. When gene sequencing of bacteria 
increased dramatically in the early 1990´s, Wolbachia was included 
in the family Anaplasmataceae together with the genera Ehrlichia, 
Neorickettsia, and Anaplasma
61
. Wolbachia is vertically transmit-
ted (also called mother-to-child transmission). In insects, it is 
common in both the male and female germlines but in the nema-
todes, it is present only in the female germline.  Wolbachia is be-
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lieved to have a neutral relationship with its host, existing as an 
endosymbiont
62
. 
Recently, Wolbachia got new attention when it was discovered that 
the bacteria have antiviral properties and are able to reduce the lev-
els of dengue virus and other mosquito‐borne human pathogens by 
upregulating immune effector genes when infecting the vector spe-
cies
63
. So far, the only human infection with Wolbachia is the role 
the bacteria play in lymphatic filariasis (elephantiasis). This is a 
disease caused by parasitic worms that need the endosymbiont 
Wolbachia to infect and survive in the human lymphatic system
64
. 
When the worms located in the lymph system die they release the 
bacteria into their hosts thereby triggering an inflammatory re-
sponse
64
. 
Anaplasma 
In 1910, Theiler identified the first Anaplasmataceae species, Ana-
plasma marginale
65
. This pathogen was found in the red blood 
cells of cattle that suffered from severe anaemia. There are two 
more species in the genus that also infect ruminants: A. centrale 
(actually A. marginale ss centrale) and A. ovis. A. marginale is 
host-specific and is the major cause of anaplasmosis in cattle and 
has the widest geographic distribution among tick-borne patho-
gens, whereas A. ovis is a pathogen of sheep. A. centrale is less 
pathogenic for cattle and has been used as a live vaccine in Israel, 
Australia, Africa and South America
66
. A. phagocytophilum has 
been known to cause disease in domestic ruminants in Europe 
since 1951
67
. The bacteria were first classified as Rickettsia phago-
cytophila since they were assumed to belong to the class Rickett-
sia
67
. In 1962, they were renamed Cytocetes phagocytophila due to 
morphological similarities with Cytoecetes microti, an organism 
that is found in polymorphonuclear cells of voles
68
. In 1974, it 
changed name again to Ehrlichia phagocytophila and in 2001 after 
the reclassification of the genus Ehrlichia, the current name was 
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created
21,69
. In the beginning of the 1990s, the first human case of 
infection was described – a patient who died of severe febrile ill-
ness two weeks after a tick bite
70
. Small bacteria were discovered 
within the neutrophils in the blood of the patient and serological 
assays for the human monocytic ehrlichiosis (HME) agent, Ehr-
lichia chaffensis were negative. Even if serological assays indicat-
ed identical relationships to the veterinary pathogen, E. 
phagocytophila, the human agent was named human granulocytic 
ehrlichiosis (HGE) agent at that time
70
.  A. phagocytophilum has, 
as its name implies, favouritism for phagocytic cells, and is one of 
very few bacteria that survive and replicate within neutrophilic 
granulocytes
21
. 
 
The bacterium counteracts neutrophil-mediated bacterial killing by 
triggering an anti-apoptotic cascade, which is important for its in-
tracellular survival in the normally short-lived neutrophilic granu-
locytes
21,71
. In nature, the life cycle of A. phagocytophilum consists 
of mammalian and tick stages
53
.Viable A. phagocytophilum organ-
isms have been isolated from several mammalian hosts, e.g. cattle, 
sheep, dogs, horses and humans. In Europe, wild animals such as 
mice and bank voles are the primary reservoirs but domestic ani-
mals such as dogs can serve as secondary reservoirs for human in-
fection
21
. 
Ehrlichia 
 
The Ehrlichia genus contains five well-recognized species accord-
ing to current taxonomy: E. chaffeensis, E. ewingii, E. canis, E. 
muris and E. ruminantium
69
. There are also a number of genetic 
variants of Ehrlichia that have not been clearly defined yet
72-74
. 
The main target cells for infection by Ehrlichia species of mam-
mals are cells of the blood vascular system. E. chaffeensis (the 
agent of HME), the canine pathogen E. canis and the murine path-
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ogen E. muris all multiply inside of monocytes and macrophages, 
whereas E. ewingii (the agent of HGE in humans) multiplies in 
granulocytes. E. ruminantium causes the disease heartwater in do-
mestic ruminants. E. ruminantium replicates initially in macro-
phages and neutrophils near the site of infection. When these cells 
rupture, the organism disseminates via the bloodstream to invade 
endothelial cells of blood vessels in the body and in domestic ru-
minants there seems to be a predisposition for endothelial cells of 
the brain. Vasculitis leads to effusion in various sites, including the 
pericardial sac and thereof the name “heartwater”75. Heartwater is 
only seen in the southern hemisphere and has high mortality and 
decreases herd productivity, therefore the economic impact of the 
infection is very high
76
. 
 Anaplasmataceae and the host cell 
Bacteria belonging to the Anaplasmataceae must be very flexible 
to survive in different microenvironments.  They need to escape the 
immune system during their extracellular and infective stages and 
once inside the host cell, they need to neutralize the innate immune 
response and sabotage cellular processes to be able to survive and 
replicate intracellularly. Among gram-negative bacteria, lipopoly-
saccharide (LPS) and peptidoglycan are important cell wall com-
ponents. However, bacteria belonging to the Anaplasmataceae 
have only a thin outer membrane without LPS and no peptidogly-
can; they have lost almost all genes for biosynthesis of these com-
pounds
77
. It has been suggested that cholesterol is needed to 
compensate for the lack of LPS and peptidoglycan and to maintain 
the mechanical strength of the cell wall
77
. 
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The lack of LPS facilitates the escape from macrophages and neu-
trophils since they cannot recognize pathogen-associated patterns 
(PAMP´s) such as LPS and peptidoglycan
78
. Other important 
mechanisms are the use of proteins, exemplified by the invasin 
EtpE that is required for the adhesion and invasion of the host cell 
(Fig 4). The Ehrlichia bacteria in the vacuoles (Ehrlichia-
containing vacuole) also secrete effector proteins to escape the host 
immune response (Fig 4). Bacteria belonging to Anaplasmataceae 
Figure 4. Ehrlichia´s strategies inside the host cell 
(1) The dense-cored cell enter and attach by using Invasin EtpE. (2) The bacteria 
replicate in a phagosome (Ehrlichia-containing vacuole) that secrete T1SS effector 
proteins to escape host innate immune-response. (3) The dense-cored cell differenti-
ate into reticulate cells and fuse with Transferrin-receptor endosome to acquire iron 
from the host cell and disrupt cell-signalling pathways to inhibit cytokine production 
and prevent innate immune responses. (4) Ehrlichia secretes T4SS effector protein to 
inhibit apoptosis and the reticulate cells divide to form microcolonies (morulae). The 
morulae secrete proteins to keep the mitochondria stabilized preventing triggering of 
apoptosis of the host cell. (5)  To promote intracellular survival the bacterial protein 
Rab7 acidifies the late endosome to inhibit fusion with lysosome. (6) Dense-cored 
cells are released by exocytosis or rupture of the cells. Picture adapted from Mou-
méne et al. [77] 
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can also manipulate the host cell by inhibiting or delaying sponta-
neous cellular apoptosis to be able to replicate inside the host cell, 
e.g. Ehrlichia secrete T4SS effector proteins (Fig 4)
53,79
. E. ewingii 
can stabilize the mitochondrial membrane of neutrophils (host 
cell)
80
 by unknown mechanisms but the end-result is mitochondrial 
time-out. An inactive mitochondrion will not trigger apoptosis of 
the infected cell and will not compete for nutrients with the Ehr-
lichia bacteria (Fig 4)
81
. Recent studies of the protein composition 
of Ehrlichia chaffensis vacuoles has shown that the bacterial pro-
tein Rab7 (characteristic late endosomal protein) acidifies the com-
partment at pH 5.2, which protects the vacuole for fusion with 
lysosomes
79,82
 (Fig 4). E. chaffeensis is also able to inhibit the tran-
scription of the cytokines IL-12, IL-15 and IL-18, thereby inhibit-
ing the production of INF-ɣ from TH1 and NK cells, which 
reduces the activation of macrophages. In that way, Ehrlichia 
avoids intracellular killing by macrophages
79
.Type IV secretion 
system (T4SS), is the general mechanism by which bacterial cells 
secrete or take up macromolecules.  Bacteria belonging to the Ana-
plasmataceae have multiple copies of T4SS components and this 
system is up-regulated during infection
83
. The system secretes ef-
fector proteins, e.g. Ank 200 into the eukaryotic host cell and 
thereby facilitates intracellular bacterial survival, growth and viru-
lence
53,79
. 
Genomes 
The genomes of bacteria in this family are small (A. phagocytophi-
lum 1.47 Mb, A. marginale 1.19 Mb, E. ruminantium 1.52 Mb, E. 
chaffeensis 1.18 Mb and N. sennetsu 0.859 Mb
53,84-86
), one quarter 
of the size of that of Escherichia coli. This is believed to result 
from reductive genome evolution, i.e., the intracellular bacteria 
have gotten rid of genes required for an extracellular lifestyle
87
. A 
remarkable finding in the E. ruminantium genome is the large 
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number of repetitive sequences, constituting 8.3 % of the chromo-
some, which results in the largest genome size in the family
84
.  
 
The genes that are absent from members in the family Anaplasma-
taceae are genes that encode proteins belonging to the category of 
central intermediary metabolism
53
. Obligate intracellular bacteria 
are unable to synthesize all the organic compounds required for 
growth (also known as an auxotroph) and acquire most amino acids 
and other metabolites from the host. A considerable part of the ge-
nome of these bacteria encodes outer-membrane protein 1 (OMP1) 
genes and some of them are unique to the family of Anaplasma-
taceae 
86
. OMPs have many functions: ensuring the integrity and 
stability of the bacterial envelope, passive and active transport of 
substrates and nutrients by forming porine channels, cell-to-cell 
communication and adhesion to host cells. Since Ehrlichia spp. and 
Anaplasma spp. lack LPS these envelope OMP proteins are as-
sumed to be a major part of the bacterial surface that is exposed to 
the host
53
.  
 
The expansion of OMP1 genes is shown by the repeats in the ge-
nomes of Anaplasma spp. and Ehrlichia spp. Moreover, other func-
tionally important genes such as the type IV secretion genes, are 
duplicated and contribute to the repeats
86
.One interesting thing, is 
that different OMPs are expressed in different host/vector cell 
types. In A. phagocytophilum, a higher proportion of up-regulated 
genes encoding OMPs are seen in human cell lines than in tick cell 
lines
88
. In contrast, the E .ruminantium MAP1 (OMP protein orga-
nized as a porin) gene is expressed only in tick cells (vector) and 
not in mammalian host cells
89
. Since OMP1 proteins are highly 
immunogenic they are good candidates as vaccine 
components
53,54,79
. Among nonliving vaccines, purified outer 
membranes have provided the best protection against infection and 
disease
90
. 
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Candidatus Neoehrlichia mikurensis 
Basic characteristics 
Candidatus Neoehrlichia mikurensis is assumed to be an obligate 
intracellular gram-negative bacterium like the other members of the 
family Anaplasmataceae. This new bacterial species was named 
after its discovery in ticks and rodents on the Japanese island of 
Mikura in 2004
91
. The term Candidatus specifies that this bacte-
rium is so far uncultivable
92
. However, we recently managed to 
cultivate this bacterium from six clinical isolates, so hopefully this 
prefix can be removed in the near future and the bacterium can be 
renamed Neoehrlichia mikurensis
93
. Before Kawahara’s findings in 
2004, the same bacterial species had been described and given oth-
er Ehrlichial names. Schouls et al. first described this agent in 
1999, as an Ehrlichia-like species when it was found in Ixodes rici-
nus ticks collected in the Netherlands
94
. In the beginning of 2000, 
several reports followed from Norway, Russia and Italy about this 
new Ehrlichia-variant in Ixodes ticks
95-97
. Shpunov et al called this 
new species “Ehrlichia-like Schotti variant” when it was found in 
ticks in the Baltic region of Russia
98
 and in 2003 the first identifi-
cation of this Ehrlichia-like organism in small mammals were re-
ported from China
99
.  
 
In 2004, Kawahara et al. showed an electron micrograph of an en-
dothelial cell from the spleen of a rat with rounded, pleomorphic 
structures with a diameter of 0.5-1.2 µm
91
. These membrane-bound 
inclusions containing small cocci were the result of intraperitoneal 
infection of a laboratory rat with spleen homogenate from wild 
Rattus norvegicus that was PCR-positive for this new agent
91
. The 
structures inside the cytoplasm of the endothelial cell of the rat 
were not labelled with DNA probes or antibodies so it was not 
proven formally that this picture really displayed Ca. N. mikuren-
sis. 
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Comparisons of the 16S rRNA and the groEL gene sequences of 
these Ehrlichia-like organisms revealed that this new bacterial spe-
cies belonged to a new cluster in the family of Anaplasmataceae. 
More recently, new members have been added to the cluster of 
Candidatus Neoehrlichia: Candidatus Neoehrlichia lotoris (detect-
ed in raccoons from North America)
100
; Candidatus Neoehrlichia 
sp. FU98 (closely related to Candidatus Neoehrlichia lotoris and 
found in red foxes, a badger and one Ixodes rugicollis tick from 
Europe)
101,102
; Candidatus Neoehrlichia “Tanzaniae”, detected in 
an immune competent young women from Austria believed to have 
contracted a febrile infectious disease in Tanzania
103
; Candidatus 
Neoehrlichia australis and Candidatus Neoehrlichia arcana, both 
described in Ixodes holocyclus ticks from Australia
104
.  
Epidemiology 
The main vector of Ca. N. mikurensis is the Ixodes ricinus tick. 
This tick is widely distributed in Europe and many studies have 
shown that Ca. N. mikurensis is the third most common tick-borne 
pathogen in Europe after Borrelia and Rickettsia species
105,106
. Ca. 
N. mikurensis has been detected in ticks and rodents in several Eu-
ropean countries, but also in China, Japan, Russia, Mongolia and 
South Korea
107,108
. So far, no Ca. N. mikurensis has been reported 
in ticks, humans or mammals from either the United Kingdom 
(UK) or America. The bacterium has been identified in I. ricinus 
collected both from the vegetation (prevalence of infection between 
0.1-24% ) and from wild and domestic vertebrates (0.3-31%)
108
. It 
has also been shown that Ca. N. mikurensis-infected ticks can be 
co-infected with other bacterial pathogens where Borrelia burgdor-
feri sensu lato seems to be the most common agent
108
.  Besides de-
tection in ticks belonging to the Ixodes species, it has been reported 
that this agent has been found in Dermacentor reticulatus in Ger-
many
109,110
 and in Haemaphysalis concinna in Mudanjiang, 
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China
111
, but these few cases have probably no epidemiological 
relevance in the transmission of Ca. N. mikurensis.  
 
The prevalence rates of Ca. N. mikurensis in ticks and wild ani-
mals seem to follow a seasonal pattern with low or no prevalence 
in May, increasing rates in June and July and the highest peaks in 
August (Germany)
112
, September (Sweden)
113
 or October (Nether-
lands)
114
. The prevalence of Ca. N. mikurensis in wild rodents var-
ies between 1.1-27 % in China, 0-100% in Europe (4-19% in 
Sweden)
115
. 
Pathogenesis and transmission 
Ca. N. mikurensis has been found in all stages of Ixodes ricinus 
ticks even if reports of detection of the bacterium in the larval stage 
are questionable since no vertical transmission seems to occur. 
116,117
. The high prevalence of Ca. N. mikurensis in wild rodents 
(double that of prevalence in ticks) indicates that rodents are the 
reservoir of the infection that ensure the survival of Ca. N. miku-
rensis in the environment 
112
.  
 
Several species of wild rodents has been described acting as reser-
voirs for the bacterium e.g voles, mice, rats and 
chipmunks
91,112,118,119
. The rodents do not seem to get affected by 
the bacteria and they are able to clear the infection by 
themselves
120
. The only known animal besides humans that gets 
symptomatic infection by Ca. N. mikurensis is the dog
121,122
.  
 
The transmission of Ca. N. mikurensis to humans is believed to 
occur via tick bites. The bacterium is inoculated through the skin 
via the bite of an infected tick. Many patients recall tick bites but 
this is not always the case, which is a known phenomenon with 
tick-borne infections
123
. Theoretically, it is possible that transmis-
sion of the infection can occur by blood transfusion, which has 
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been reported by other agents in the family of 
Anaplasmataceae
25,124
. 
 
The target cells of Ca. N. mikurensis in humans have been sug-
gested to be both granulocytes and endothelial cells
91,125
. Recently, 
we published the successful cultivation of this agent in human en-
dothelial cell lines, which has been our first choice of target cells 
since there is a high incidence of vascular events in patients diag-
nosed with neoehrlichiosis
93
. The endothelial cell lines were de-
rived from skin microvasculature and the pulmonary artery, 
respectively, and the infection was transferred from infected tick 
cell lines. 
 
Figure 5A displays cells from the tick cell line IRE/CTV20 (tick 
cell line derived from Ixodes ricinus) infected with whole blood 
from a patient diagnosed with neoehrlichiosis. The photo is taken 8 
weeks after inoculation. Small coccoid bacteria in cytoplasmic in-
clusions close to the cell nucleus can be visualized. This is the 
Figure 5 Visualization of Candidatus Neoehrlichia mikurensis infection in 
cell lines  
A) Giemsa-stained cytocentrifuged smears of tick cells (IRE/CTVM20) in-
fected in vitro with Candidatus Neoehrlichia mikurensis. B) Giemsa-stained 
preparation of a cutaneous microvasculature endothelial cell infected in 
vitro by Candidatus Neoehrlichia mikurensis. Arrows indicate bacterial in-
clusions. Photo by L.Wass © 
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same location that Yabsley et al. described for Candidatus Neoehr-
lichia lotoris, the closest relative of Ca. N. mikurensis
100
.  
The same phenomenon could be visualized in experimentally in-
fected tick cells using Image flow cytometry (Fig. 6). The labelled 
bacteria appear in compact inclusions close to the host cell nuclei 
(Fig. 6). The close location to the host cell nucleus can be im-
portant for the bacteria for easy delivery of molecules (nucleomod-
ulins) to hijack nuclear processes by targeting host DNA. Studies 
has indicate that nuclear delivery of factors by intracellular bacteria 
can sabotage host defences by directly interfering with transcrip-
tion, chromatin‐remodelling, RNA splicing or DNA replication and 
repair of the host cell
126
. 
 
Our finding that endothelial cell lines are permissive for Ca. N. 
mikurensis infection together with our identification of the bacteria 
within so called “circulating endothelial cells” of infected patients 
strongly suggests that vascular endothelial cells are a target of the 
infection in humans
93
. Regarding the discovery by Pekova et al. 
demonstrating bacteria-like structures inside granulocytes of in-
fected patients, it is possible that this finding reflected that the bac-
teria had been phagocytosed rather than infection of granulocyted 
by Ca. N. mikurensis
125
. If granulocytes were indeed the targets of 
this infection it should have been easier to localize the bacteria in 
Figure 6 Image flow cytometer illustration of tick cells infected with Candidatus Neoehr-
lichia mikurensis. Tick cells from cell line IRE/CTVM shown after 25 weeks of inoculation 
with an infected blood sample from a human patient. The cells were labelled using 
panbacterial DNA probe (EUB) and Candidatus Neoehrlichia mikurensis-specific DNA 
probe (NEO). Red staining (DRAQ5) displays the host cell nucleus and the overlay im-
age of all stains shows bacteria in the cytoplasm close to the host cell nucleus. 
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stained blood smears of infected patients. We have examined many 
blood smears from different patients and never detected any moru-
lae or coccoid structures, nor have any other research groups. 
However, a close relative of Ca. N. mikurensis, Ehrlichia rumina-
tium, infects both vascular endothelial cells and circulating neutro-
phils so there is a possibility that Ca. N. mikurensis acts in the 
same way
127
.  
Clinical picture of neoehrlichiosis  
The first case reports of human infection with Ca. N. mikurensis 
were published in 2010
128-130
. In 2014, we published an overview 
of the clinical picture of this new infectious disease, and together 
with our collaborators proposed to name this new infectious dis-
ease “neoehrlichiosis”131. Neoehrlichiosis is difficult to diagnose, 
especially among immune compromised patients, where the dis-
ease can mimic non-infectious conditions
131
. The most frequent 
symptoms in immune compromised patients are high remitting fe-
ver with chills and nightly sweats, migrating or localized pain 
(neck, temporal joint, knees, ankles or different muscles)
115,131
.  
 
Different types of skin rashes that can look like erysipelas or ery-
thema nodosum can also occur
115
. There are patients that report less 
specific symptoms like diarrhoea, cough, and weight loss, most of 
which result from prolonged systemic inflammation
115
. However, 
the most severe findings among these patients are the high inci-
dence of thromboembolic or vascular complications
115
. These 
events most often affect the venous part of the circulation, giving 
rise to deep vein thrombosis in the arms or legs but even pulmo-
nary embolisms have occurred. Other frequent vascular complica-
tions are inflammation of superficial veins (thrombophlebitis) that 
can be extremely painful but there are also cases with severe arteri-
al inflammation resulting in aneurysms or transitory ischemic at-
tacks
128,131,132
. All these vascular events can result from infection of 
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the endothelial cells in the blood vessels and/or by the inflammato-
ry response to the bacterial infection. In figure 7 the most common 
clinical signs in 27 diagnosed Swedish immune compromised pa-
tients are listed together with the most deviant laboratory parame-
ters. The most typical laboratory findings among the patients are  
 
 
 
 
 
 
increased acute phase reactant C-reactive protein (CRP) in serum, 
leukocytosis due to elevated levels of neutrophils, and anaemia. 
Moderately lowered platelet counts and slightly increased hepatic 
transaminases are less common
115
. 
 
Until recently, severe symptoms associated with neoehrlichiosis 
have mainly been seen in immune compromised patients. Howev-
er, some of the last patients that we have diagnosed at our clinic, 
Clinical Microbiology Sahlgrenska University Hospital, have been 
Figure 7 Common clinical signs and laboratory parameters among immune sup-
pressed patients with neoehrlichiosis. All patients have systemic inflammation 
demonstrated by high fever. Different types of pain, such as migrating muscle pain 
are also common. There are also a high rate of vascular and thromboembolic events. 
Increased C-reactive protein (serum), elevated blood cell count and anaemia are the 
most typical laboratory parameters. Abbrevations: B, blood; S, serum 
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immune competent and some have been afflicted by severe vascu-
litis or thrombosis (data not published). All of the patients have 
been extensively investigated at their hospitals but none of them 
reported fever and they did not have abnormal laboratory parame-
ters that pointed at infection. The patients also had lower loads of 
bacteria in their blood than what is seen among immune compro-
mised patients. These are still unpublished cases but there is one 
published case from Germany with a fatal outcome of an immuno-
competent patient
129
. This patient died due to an aneurysm of a 
cerebral artery that haemorrhaged. A post-mortem PCR analysis of 
a blood sample taken on the first day at the hospital showed infec-
tion with Ca. N. mikurensis. 
 
The clinical picture of neoehrlichios in immune competent individ-
uals can vary greatly. Asymptomatic or milder infection with fever 
and additional malaise, headache or stiff neck can be seen 
111,133
. 
There are seven reported cases from Norway of immune competent 
patients who had EM after tick bite and where Ca. N. mikurenis 
was detected in blood, and no evidence of Borreliosis 
134
. 
 
The incubation period between exposure to Ca. N. mikurensis and 
infection is still not clarified. It is hard to calculate since most of 
the patients have been investigated for their symptoms during a 
long time leading to considerable delay in diagnosis. A Chinese 
study suggests that the incubation period in immune competent 
persons has a range of 2-35 days
111
. Our two published immune 
competent patients had no measurable DNA levels in their blood 
when they attended the study at day 0. Both patients sought medi-
cal care because of rash after tick bites on day 77 respectively day 
65, when Candidatus Neoehrlichia DNA could be detected. In im-
mune suppressed patients, one would guess that the onset to infec-
tion would be shorter but many of our patients developed their first 
symptoms during the winter period
135
. This gives a rather long in-
cubation time since no ticks are active in Sweden after November 
(ticks do not quest for host at temperatures below 5˚C). 
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Risk factors and immune response 
Several factors make patients predisposed to develop severe ne-
oehrlichiosis. Diseases like haematological malignancies (lym-
phoma and chronic lymphocytic leukaemia), autoimmune diseases 
(multiple sclerosis, or psoriasis) and rheumatic diseases (rheuma-
toid arthritis, systemic lupus erythematosus and granulomatosis 
with polyangiitis) have been described as underlying 
conditions
131,132,135
. Higher age, recent chemotherapy, corticoster-
oid treatment or treatment with rituximab is other risk factors. 
Rituximab is a monoclonal antibody directed against CD20 on B-
cells and in Sweden this drug is used extensively among multiple 
sclerosis patients. Rituximab is also used to treat malignant B-cell 
lymphomas and a variety of systemic rheumatic diseases so the 
numbers of patients receiving this treatment is rather high. Sple-
nectomy is also a predisposing factor for Neoehrlichial-infection; 
this organ is the largest lymphoid structure in the body with nu-
merous immunological functions.  
 
Many of the patients diagnosed with neoehrlichiosis have been 
splenectomised and have developed severe disease. The fact that 
many of the patients are splenectomised or have underlying diseas-
es that affect the B-lymphocytes and are treated with rituximab 
(reducing the B-cells) indicates that B-cells are important immune 
cells to fight the infection. According to most of the literature, the 
adaptive humoral immune response which includes the antibody 
production from B-cells is not the first line defence against intra-
cellular pathogens since the microbes are inaccessible for circulat-
ing antibodies
136
. However, Li et al. have shown that Ehrlichia 
chaffeensis can be found outside of host cells during an active in-
fection, which makes them susceptible to antibody-mediated host 
defence explaining the importance of humoral immunity
137
. B-
lymphocytes produce antibodies and convey immune memory. It is 
mainly neutrophils, macrophages and natural killer (NK) cells that 
mediate the innate immune response to intracellular pathogens. The 
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bacteria stimulate macrophages and dendritic cells to produce IL-
12, which activates the NK-cells and they produce INF-ɣ that acti-
vate the macrophages, which promotes killing of the phagocytosed 
bacteria (Figure 8). However, innate immunity usually fails to 
eradicate the infection since intracellular bacteria are good at 
evolving strategies to resist elimination by phagocytes
138
. Patients 
with neoehrlichiosis have raised levels of leukocytes, in particular 
neutrophils
131
. This proves the involvement of these cells in infec-
tion with Ca. N. mikurensis probably both regarding their function 
as phagocytes but also as “cleaners” of dead cells and bacteria.  
 
 
Eradication of intracellular bacteria requires adaptive cell-mediated 
immunity
139
. This includes activation of macrophages by INF-ɣ 
produced by Th1 cells, which enhances the ability of the macro-
Figure 8 The immune response against intracellular pathogens  
The innate immune response consists mainly of phagocytic cells, e.g. macrophages 
and neutrophilic granulocytes, natural killer (NK) cells and dendritic cells (DC). To elim-
inate the infection activation of adaptive cell-mediated response with T-cells is neces-
sary. Abbreviations IL, interleukin; INF, interferon, TNF, tumour necrosis factor; ROS, 
reactive oxygen species; NO, nitric oxide.  
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phage to produce substances like reactive oxygen species (ROS), 
nitric oxide (NO) and a large number of antimicrobial peptides, 
resulting in efficient killing of microbes that have managed to sur-
vive inside of phagocytes (Figure 8). INF-ɣ production by Th1 
cells also stimulates the production of antibodies and the activation 
of cytotoxic T-cells (CTL) that eliminate infected cells mainly by 
cell-cell interaction but also by release of cytotoxic granules
140,141
.  
Diagnosis  
Many of the patients diagnosed with neoehrlichiosis have been in-
vestigated for long periods of time to find the cause of their symp-
toms; the longest period among the patients that were diagnosed at 
the Department of Clinical Microbiology at Sahlgrenska Hospital 
was 1.5 years. Several patients have also been treated with various 
broad-spectrum antibiotics before they were diagnosed with ne-
oehrlichiosis
131
. The delay of diagnosis probably has several rea-
sons. (1) The bacterium does not grow in cell-free media such as 
blood culture bottles. (2) This is still a rather new infectious dis-
ease so the awareness among physicians is still very low. (3) The 
symptoms are often interpreted to be non-infectious and attributed 
to underlying diseases (recurrence of a hematologic malignancy or 
bout of systemic rheumatic or other autoimmune disease). (4) The 
diagnosis currently relies on molecular techniques such as pan-
bacterial or specific PCR, which are only available at a few clinical 
laboratories. 
 
Pan-bacterial PCR directed against the 16S rRNA gene is the most 
widely available diagnostic option for Ca. N. mikurensis at the 
moment. This assay is performed in clinical laboratories both in 
Sweden and in the wealthy parts of the world. Specific PCR done 
on clinical samples that is directed against the housekeeping genes 
groEL or 16S rRNA of Ca. N. mikurensis is in Sweden currently 
only analysed at the Department of Clinical Microbiology at 
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Sahlgrenska University Hospital. We have chosen to include a pos-
itive control plasmid in the PCR to enable calculation of the bacte-
rial burden in analysed samples. Several studies have shown that 
infected immunosuppressed patients have a very high bacterial 
burden in blood
131,142
. The types of human samples that have yield 
positive PCR results in neoehrlichiosis patients so far are blood 
components (plasma, serum, whole blood and blood culture bottle 
contents), bone marrow and a skin biopsy 
143
. Our experience is 
that the specific Neoehrlichia PCR has a better sensitivity in plas-
ma than in whole blood. So far, no one has reported that Candida-
tus Neoehrlichia DNA has been detected in cerebrospinal fluid 
even if neurological symptoms have been observed in a few pa-
tients
131
. 
Treatment 
The recommended treatment for neoehrlichiosis is oral doxycy-
cline, 100 mg twice daily for three weeks. In case of hypersensi-
tivity to doxycycline, Rifampin (300 mg twice a day for 3 weeks) 
also gives a complete response
115
.We have also information regard-
ing treatment failure when using a too low dose of doxycycline 
(100 mg once daily for 10 days preceded by a 200 mg start-up 
dose). The patient in question cleared his fever (which was deemed 
to be of uncertain origin and the treatment was empiric) and rapidly 
improved. However, 40 days after treatment the patient regained 
fever and stiff neck and follow-up PCR was positive for Ca. N. 
mikurensis. After adequate treatment with 200 mg doxycycline dai-
ly for 3 weeks, the patient achieved full recovery and the PCR was 
negative
24
. Most cases with neoerhlichiosis improve rapidly once 
given targeted antibiotics.  
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Aims 
The aims of this thesis were: 
    To map this new infectious disease with respect to what 
types of patients that are afflicted, the clinical picture dis-
played by the patient categories, and the pattern of laborato-
ry findings seen in infected patients.  
    Investigate if Candidatus Neoehrlichia mikurensis is only 
an opportunist that afflicts immune compromised patients 
or if immune competent persons can become sick. 
    Establish the genetic relatedness of Candidatus Neoehr-
lichia mikurensis strains derived from patients in Europe. 
    Perform de novo whole-genome sequencing of Candidatus 
Neoehrlichia mikurensis  
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Methods, Results and Discussion 
Paper I 
Data collection 
Adult Swedish patients with possible ongoing Ca. N. mikurensis 
infection were recruited to the NEO-VÄST study. That is: a) pa-
tients that displayed at least one sign of systemic inflammation (fe-
ver, elevated inflammatory parameters such as C-reactive protein, 
erythrocyte sedimentation rate, white blood cell counts, etc.) b) 
among immunocompromised patients, e.g. haematology and rheu-
matology patients, and c) those with suspected recurrence of under-
lying disease but where something seemed amiss. 
 
Study patients were examined by a physician according to a study 
protocol and various symptoms and clinical signs were noted as 
well as possible exposure to ticks. Host factors such as age, gender, 
underlying disease, immunosuppression including lack of spleen, 
and ongoing medication were registered. Blood samples were col-
lected for clinical microbiological diagnosis of Ca. N. mikurensis, 
and blood chemical work-up. Serum samples were stored frozen 
for later immunological analyses. The Local Ethics Committee in 
Göteborg (394-12), Sweden approved the study in 2012. In paper I, 
all of the Swedish patients were from the NEO-VÄST study. Data, 
symptoms, follow-up and origin of the non-Swedish patients in this 
paper had been published before
125,129,142
. From the Swedish pa-
tients, the clinical and laboratory data were mainly derived from 
the patient’s journals but also from attending physicians. Medical 
histories were reported by the patients themselves. GraphPad Prism 
5.0 software was used for calculations. 
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Polymerase chain reaction 
The diagnosis of neoehrlichiosis was based on PCR analysis of 
blood samples in all cases. EDTA-blood from the Swedish patients 
was processed at the Department of Clinical Microbiology Labora-
tory as follows: the plasma was concentrated (1600 x g for 5 
minutes) and then DNA was extracted by a MagnaPure compact 
extraction robot (Roche, Basel, Switzerland) according to the man-
ufacturer’s protocol. This was not done for patient 1’s sample, 
which was extracted manually with enzymatic treatment as previ-
ously published 
144
. The DNA samples were then analysed with 
pan-bacterial PCR targeting region V1-V4 of the 16S rRNA gene 
(base pairs 23-806), followed by Sanger sequencing as described 
previously
144
. The sequences were analysed with the GeneBank-
BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and 
showed 100% similarity to Candidatus Neoehrlichia mikurensis. 
For the patients diagnosed in Germany and Switzerland, almost the 
same procedures were performed; extraction from blood with ex-
traction robot EZ1 (Qiagen, Hilden, Germany) in Switzerland or 
manually by QIAamp DNA mini kit (Qiagen, Hilden, Germany) in 
Germany, and pan-bacterial PCR against V1-V4 (base pairs 10-806 
in Switzerland and base pairs 8-806 in Germany) followed by se-
quencing
129,142
. For the patients that were diagnosed in the Czech 
Republic, the extraction technique of the peripheral blood samples 
was not reported and the pan-bacterial PCR was against region V4-
V8 (base pairs 783-1389) of the 16S rRNA gene
125
. 
 
Bacterial DNA loads were calculated in 5 patients by comparing 
cycle threshold (CT)-values from real-time PCR with standard 
curve generated from serial dilutions of a positive plasmid control. 
This was performed for two patients from Switzerland with the use 
of a Ca. N. mikurensis specific real-time PCR towards the 16S 
rRNA gene
142
 and for three Swedish patients with a Ca. N. miku-
rensis specific real-time PCR against the heat shock protein 
groEL
145
. 
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Results and discussion 
This study was performed to make physicians aware of this new 
infectious disease that chiefly afflicts patients with certain autoim-
mune diseases or hematologic malignancies. The goal was to map 
this new disease to inform about neoehrlichiosis to avoid unneces-
sary suffering for affected persons. Many of these patients had 
been investigated by several different specialists during a long time 
before they were diagnosed with neoehrlichios. All but one of the 
patients had been hospitalized and two were admitted more than 
once. Several of the patients received immune suppressive therapy 
as a treatment against their symptoms since no infectious agent was 
discovered and the condition with systemic inflammation indicated 
recurrence of the underlying morbidity. 
 
The 11 investigated patients in this study were all middle-aged or 
elderly. All patients had underlying diseases that influence the 
adaptive immune system (Table 2). Many of the patients (8/11) had 
no spleen, which in most cases had been removed due to their un-
derlying disease. All patients had received some type of chemo-
therapy and/or immune suppressive treatment (7/11 systemic 
corticosteroids, 5/11 Rituximab, 4/11 Cyclophosphamide and 1/11 
Methotrexate). Despite the high administration rate of immune 
suppressive treatment and the diagnostic delay, no patients died of 
the infection. The patients had high loads of bacterial DNA both in 
blood and in bone marrow (median value 2 x 10
6
 bacterial gene 
copies/mL). This calculation is based on the assumption that Ca. N. 
mikurensis contains only 1 copy of the 16S rRNA gene and of the 
groEL gene, respectively. This theory seems to be correct since we 
have now managed to perform de novo whole-genome sequencing 
and annotation of these genes (paper IV). The heavy burden of bac-
teria in these patients probably reflects their impaired immune state 
since we haven’t noticed these low CT-values among immune 
competent patients.  
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All patients had high fever with peaks of up to 40˚C and many ex-
perienced chills and nightly sweats. The majority (8/11) was both-
ered by different types of localized pain (migrating muscle pain, 
stiff neck, joint pain and tender subcutaneous veins). Less common 
symptoms were skin rashes of the lower extremities, diarrhoea, 
swollen ankles, cough and weight loss. The pain in subcutaneous 
veins and the swollen ankles was probably due to infection of en-
dothelial cells since it has been established that endothelial cells 
are one target cell of infection for Ca. N. mikurensis
93
. The most 
severe findings among these patients and the clinical sign that 
seems to characterize neoehrlichios are the vascular and thrombo-
embolic events that occur among many of the patients (6/11 in this 
study). Two patients had deep vein thrombosis above the knee, one 
patient developed deep vein thrombosis in both the upper arm and 
leg and one patient developed deep vein thrombosis, pulmonary 
embolism and transitory ischemic attacks. There was an additional 
patient with transitory ischemic attacks and both patients had re-
Table 2 Host factors of the studied patients diagnosed with neoehrlichiosis 
 
 
Abbreviations: M, male; F, female; B-CLL, B-cell chronic lymphocytic leukemia; SLE,  Systemic 
lupus erythematosus; T-LGL, T-cell large granular lymphocyte leukemia; DLCBL, diffuse large B-
cell lymphoma; CLL, chronic lymphocytic leukemia; PTLD, post-transplant lymphoproliferative 
disorder. 
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peated ischemic episodes that engaged both sides of the body. One 
patient also suffered from severe arterial inflammation with aneu-
rysms.  
 
The pathogenic mechanism behind these complications probably 
depends on infection of the endothelial cells. But there may be ad-
ditional pathogenic mechanisms involved. Blood clot formation 
can be a process to limit an infectious process that cannot be con-
trolled by the immune system
146
. The vascular complications may 
indicate that the depressed B-cell immune responses displayed by 
many of these patients might reflect that B-cells are important for 
elimination of this bacterium. It has been shown that B-cells and 
antibodies can play an important role in host defence against an 
intracellular infection, and not only T-cell immunity, which is con-
sidered as the main defence mechanism
147
.  
 
A well-functioning spleen in the fight of the infection is probably 
also important since many of the patients lacked the spleen. Since 
the spleen is one of the sites where natural IgM antibodies are pro-
duced, an important part of the innate immune system, we investi-
gated whether patients with severe neoehrlichiosis might have low 
levels of such antibodies. However, half of the patients had de-
pressed levels, and half had normal levels of natural IgM antibod-
ies, and no relationship with splenectomy was seen
148
. We 
speculate that the main function of the spleen in the fight against 
neoehrlichiosis infection may be the production of specific IgM 
and IgG from memory B-cells
148
. 
The only consistent laboratory finding among the patients was the 
raise of the acute phase reactant C-protein in serum (19-370 mg/L; 
reference level <5 mg/L). Raised levels of white blood cells (9/11) 
and of serum lactate dehydrogenase (5/11) with anaemia (9/11) and 
hyponatremia (6/11) were also common parameters. Lowered 
platelet counts and elevated liver enzymes were rare findings.  
 
 
MET HO DS,  RESULT S AND  DI SCUSSI O N 37 
These are common laboratory finding among patients with system-
ic inflammation and nothing that is specific for neoehrlichiosis, 
which also makes these patients more difficult to diagnose. Diag-
nosis currently relies on pan-bacterial or specific PCR, which are 
not used as first-line procedures in febrile patients, especially not 
on blood samples, where cultivation in cell-free blood culture bot-
tles is the gold standard.  
 
All patients in this study recovered within a week after doxycycline 
therapy was initiated. It was seen that 100 mg doxycycline twice 
daily for a 3-week period is sufficient to clear the infection and to-
day when we have more experience, we know that the dosage used 
for empiric treatment of infections of unknown etiology (100 mg 
daily for 10-14 days) is not enough to clear the infection with Ca. 
N. mikurensis as documented for one neoehrlichiosis patient who 
relapsed
24
. 
Paper II 
Patient population 
The Tick-Borne Diseases (TBD) STING-study was initiated in 
2007 by researchers at Linköping University
149
. The aim of the 
study was to investigate the prevalence of pathogens in ticks that 
have fed on humans and the risk of developing tick-borne diseases 
after a bite by an infected tick. Blood samples (EDTA blood and 
serum) from tick-bitten persons residing in Sweden or the Åland 
Islands, Finland were collected. The patient samples, two different 
health questionnaires, and the ticks that had bitten the persons were 
collected at the study’s 34 primary health care centres, both at the 
time of inclusion in the study and at the end of the 3-month study 
period. If study participants developed symptoms during the study 
period they were asked to visit a health care centre where a physi-
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cian examined them, filled in a questionnaire, and collected new 
blood samples. The patients were treated with antibiotics at the 
doctor’s discretion. The study was approved by the Ethics Commit-
tee of the Medical Faculty, Linköping University (M132-06), and 
by the local Ethics Committee of Åland Health Care, 2008-05-23. 
All patient samples in paper II were frozen plasma or serum sam-
ples from patients recruited to the STING-study. We analysed the 
102 out of 3248 participants who had sought medical care during 
the 3-month study period. 
Polymerase chain reaction 
Bacterial DNA was extracted from 400 µl of EDTA-plasma with a 
MagnaPure Compact extraction robot (Roche, Basel, Switzerland). 
A newly designed real-time PCR for clinical use, specific for Ca. 
N. mikurensis were used. The PCR was developed based on ho-
mology analysis of the groEL genes present in public databases. 
Detailed methodology is described in paper II. A 169-bp segment 
of the house keeping gene groEL was selected and a Taqman probe 
with fluorescent label fluorescein (FAM) was created. The speci-
ficity of the assay was difficult to test because of the lack of DNA 
from closely related species. Therefore we decided to confirm all 
positive samples with 16S-rRNA PCR followed by sequencing 
(described in paper I). The analytical sensitivity of the assay was 
determined using a synthetic plasmid that contained the 169-bp se-
quence of the groEL gene cloned into a pUC57 vector (Genescript, 
Piscataway, NJ, USA) and the limit of detection was 4 copies of 
the groEL gene. To evaluate the suitability of the specific assay in 
the routine diagnostic laboratory, patient specimens from earlier 
diagnosed neoehrlichiosis patients were tested and compared to the 
results of the pan-bacterial 16S rRNA PCR assay and complete 
concordance was shown. By generating a standard curve from 10-
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fold serial dilutions of the positive control plasmid we were able to 
estimate the number of groEL gene copies in patient samples. 
Anaplasma phagocytophilum serology 
A commercial indirect immunofluorescence antibody (IFA) assay 
for analysis of IgG antibodies to a human isolate of A. phago-
cytophilum (Focus Diagnostics, Cypress, CA, USA) was used ac-
cording to the manufacturer’s recommendations. Diluted patient 
serum (1:64) was placed on a glass slide coated with A. phago-
cytophilum-infected HL-60 cells and incubated. After incubation 
the slide was washed and each well overlaid with fluorescein-
labelled antibody to human IgG and incubated. The slide was then 
washed, mounted and examined by fluorescence microscopy. Posi-
tive reactions appear as green fluorescent dots within the cells. Se-
rum samples were regarded as positive at a dilution of 1:64. 
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Borrelia serology 
Patient serum samples were analysed for antibodies against Borre-
lia burgdorferi sensu lato using the RecomBead Borrelia IgM and 
IgG Kit (Mikrogen Diagnostic, Neuried, Germany) according to 
the manufacturer’s protocol. This is a luminex-based immunoassay 
to detect antibodies against seven different Borrelia antigens and 
the technique is described in Figure 9. 
 
 
 
 
 
 
 
 
 
 
Figure 9 The luminex technique used for Borrelia serology. Patient serum is incubated to-
gether with magnetic beads covered with Borrelia specific antigens; OspC (outer surface pro-
tein C), OspA (outer surface protein A), VlsE (variable major protein-like sequence-
expressed), p100, p58, p18 and p39. The antibodies in the patient serum bind to the antigen 
on the beads. After several washes the beads are incubated with anti-human IgG or IgM 
coupled to R-Phycoerythin (PE). After a new round of washes bound antibodies are detected 
using fluorescence of PE, if a reaction between antibody-antigen has occurred. The results 
are evaluated in accompanying software, recomQuant.  
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Cytokine measurements 
Cytokine levels in patient serum samples were analysed by using 
Bio-Plex 200 System (Bio-Rad, Hercules, CA, USA). A total of 20 
cytokines levels were measured by a luminex-based multiplex sys-
tem
150
.  Antibody directed against the cytokine of interest is cou-
pled to color-coded polystyrene beads. The antibody-coupled beads 
can react with a serum sample containing an unknown amount of 
cytokine, or with a standard solution containing a known amount of 
cytokine. After a series of washes to remove unbound protein, a 
biotinylated detection antibody specific for a different epitope on 
the cytokine is added to the beads. The result is formation of a 
cluster of antibodies around the cytokine. The reaction mixture is 
detected by the addition of streptavidin-phycoerythrin (PE) which 
binds to biotinylated detection antibodies. The cytokine contents in 
each test well are drawn up into the array system, which identifies 
and quantitates each specific reaction based on bead colour and 
fluorescence. Unknown cytokine concentrations are automatically 
calculated by Bio-Plex Manager software (Bio-Rad, Hercules, CA, 
USA) using a standard curve derived from a recombinant cytokine 
standard
150
. Calculation of cytokine levels were done with 
GraphPad prism 5.0. 
Results and discussion 
The goal of this study was to investigate if Ca. N. mikurensis in 
addition to being an opportunist that afflicts immune compromised 
patients might also give rise to disease in persons with normal im-
mune defences. We had the opportunity to collaborate with Linkö-
ping University and were able to analyse blood samples collected 
from healthy tick-bitten individuals participating in the STING-
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study. In this study we focused on study persons who had sought 
medical care during the 3-month study period. 
Ca. N. mikurensis DNA was detected in 2 (2%) of the 102 investi-
gated patients from the STING study. The first patient was a 
healthy 68-year old woman from southeast Sweden. She developed 
a red rash after a tick bite on her right breast 77 days after she en-
tered the study. Ca. N. mikurensis DNA was detected on day 77 
(2200 gene copies/mL) and on day 169 (200 gene copies/mL). She 
also developed IgM against Borrelia outer surface protein C 
(OspC) on day 77 and had pre-existing Borrelia-specific IgG titers 
that expanded from the inclusion to day 169. She also had un-
changed IgG against A. phagocytophilum from day 0 to day 169. 
At the health care visit on day 77, the patient was given the diagno-
sis of erythema migrans and received phenoxymethylpenicillin 
(1gx3d for 10 days) and the rash disappeared. The rash at the breast 
may have been caused by co-infection with a Borrelia spp. since 
the patient increased in the antibody titers during the study period. 
 
Patient 2 was a 57-year old woman who lived in Kalmar, Sweden. 
She had a medical history of allergy and had been treated for borre-
liosis 8 years earlier. She sought medical care on day 65 for a red 
rash on the left breast after a tick-bite 1.5 month before. She had 
lower levels of Ca. N. mikurensis DNA (260 gene copies/ mL on 
day 65 and 1300 gene copies /mL on day 98) than patient 1 and 
was seronegative for Borrelia during the entire study period. She 
had increased antibody levels of IgG against A. phagocytophilum 
throughout the study ( -/+ day 0, + day 65 and ++/day 98). She was 
also treated with phenoxymethylpenicillin (1g, 3x/d for10 days) for 
her rash. Despite being seronegative for Borrelia the rash might 
have been caused by a Borrelia spp. It is well-known that patients 
with Borrelia infections do not always develop specific 
antibodies
151
. However, it has also been shown that 20% of patients 
with erythema migrans lack detectable Borrelia DNA as deter-
mined by PCR performed on skin biopsies collected from the 
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rash
152
. This indicates that other tick-borne agents than Borrelia 
may be able to cause erythema migrans. Therefore, immune sup-
pressed patients with erythema migrans might be considered to be 
treated with doxycycline instead of penicillin to avoid development 
of severe neoehrlichiosis. Patient 2 had increasing levels of IgG 
against A. phagocytophilum during the study but this seroconver-
sion might reflect serologic cross-reactivity with Ca. N. mikuren-
sis. Wass et al showed that every fifth neoehrlichiosis patient had 
low titers of A. phagocytophilum antibodies in the blood at the time 
of diagnosis
24
.  
 
 
Table 3 Analysed cytokines and their role. 
 
Reference; Inflammation, Mölne and Wold 2007 [153] 
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This was also shown for an immune competent neoehrlichiosis pa-
tient in Switzerland
130
. Since there are relative high rates of sero-
positivity to A. phagocytophilum in Sweden in the order of 11-
17%
19,24
 despite a rather low prevalence in ticks (1.3-15%), this 
seropositivity may depend on cross-reactivity to Ca. N. mikurensis, 
which is more frequently detected in Swedish ticks (6%)
120
. 
 
The cytokine levels in serum were raised in both patients for 12 
cytokines (Table 3
153
). Out of the studied cytokines, 8 cytokines 
showed concentrations that were very low or under the detection 
limit and were therefore not further studied (IL-1ß, IL-2, IL-5, IL-
10, VEGF, PDGEF-BB, IL-13 and IL-4). An interesting finding 
was that the cytokine levels seemed to mirror the numbers of Ca. 
N. mikurensis gene copies (Paper II). The cytokine response in pa-
tient 1 may have been caused by Borrelia spp. since this patient 
had a slight increase in antibodies against Borrelia spp during the 
study. However, this patient also had the highest concentration of 
Ca. N. mikurensis (2,200 gene copies/ mL) in blood which coin-
cided with peak levels of Th1 cytokines (IL-12p70, IFN-ɣ, IP-10 
and MCP-1). This indicated that the cytokine response substantial-
ly depended on the Ca. N. mikurensis infection since Th1-like im-
mune responses are required to eliminate intracellular pathogens
140
.  
 
Both these patients were immune competent and as the most severe 
forms of neoehrlichiosis have so far mainly been detected in im-
mune suppressed patients with diseases that affect the B-cells (pa-
per I), our findings may be taken to support that B-cells are 
important for the defense against Ca. N. mikurensis since the pa-
tients in this study cleared the infection by themselves. Further 
studies on cytokines levels from these two different patient groups  
(immune suppressed vs immune competent) would be interesting 
to understand if there are dissimilar infectious defense mechanisms 
in these two patient groups. In this study we have besides the cyto-
kines involved in Th1-like response also selected cytokines based 
on findings derived from neoehrlichiosis in immune suppressed 
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patients, who present with systemic inflammation (IL-1ß, IL-6, 
TNF-α and MIP-1ß), and with neutrophilia (IL-8, IL-17A, G-CSF 
and GM-CSF). This study has shown that immune competent per-
sons may be asymptomatically infected by Ca. N. mikurensis dur-
ing a very long period and that an erythematous rash in tick-bitten 
persons in Sweden might be caused by Ca. N. mikurensis. This has 
also been noticed in a Norwegian study were seven patients with 
EM had Ca. N. mikurensis DNA in their blood 
134
. 
Paper III 
Clinical samples 
All Swedish patients in this study participated in the NEO-VÄST 
study described in Paper I. All patients were immune suppressed 
and had sought medical care due to prolonged fever and different 
symptoms consistent with neoehrlichiosis (Paper I). The patients 
were diagnosed with analysis of DNA (extracted from EDTA-
plasma) by real-time PCR targeting the groEL gene (Paper II) fol-
lowed by confirmation using pan-bacterial PCR with subsequent 
sequencing (Paper I). Details of the Czech and German patients 
have been described earlier 
125,129
 and extracted frozen DNA from 
these patients was kindly distributed by the scientists who authored 
the case studies in question.  
Multilocus sequence analysis  
A new bacterial strain is most often phylogenetically placed on the 
basis of 16S rRNA gene analysis to start with. However, there are 
disadvantages in using the 16S rRNA gene as a phylogenetic 
marker since it has insufficient resolution at species level
154
. A 
higher resolution can be obtained by performing phylogenetic 
analyses based on several protein-coding genes (housekeeping 
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genes) since they evolve at a slow but constant rate and have better 
resolution power, especially at the genus level but even below
154
. 
Internal fragments of these protein-coding genes are sequenced and 
subsequently used to calculate phylogenetic trees. Sequences that 
differ by even a single nucleotide for each gene are assigned as dif-
ferent alleles, making this kind of assay highly suitable for detect-
ing genetic changes within and between species. In 2005, Gevers et 
al. introduced this type of genotyping method called multilocus se-
quence analysis (MLSA)
155
. MLSA is based on multilocus se-
quence typing (MLST) but in MLST the downstream analyses are 
based on allele numbers and sequence types to estimate relatedness 
among isolates and it ignores the number of nucleotide differences 
between alleles. 
 
A critical point in MLSA studies is the selection of genes. It is 
clear that housekeeping genes coding for proteins with important 
functions should be considered because they are stable with respect 
to rapid genetic modifications, genes are often selected inde-
pendently for each new taxon investigated
154,155
.  
Target loci and primer design 
There were only a few limited genes that had been sequenced and 
deposited in gene banks for Ca. N. mikurensis (partial sequences of 
16S rRNA, gltA and groEL)
91
 at the start of this study. In order to 
establish a MLSA scheme we studied protocols developed for other 
species belonging to the Anaplasmataceae family, i.e., Ehrlichia 
ruminantium
156
 and Wolbachia pipientis
157
. Alignments of 10 dif-
ferent whole-genome–sequenced bacterial strains belonging to the 
Anaplasmataceae (Table 4) were done for several genes and pri-
mers were designed manually. The primers were selected to cover 
regions where the different strains had corresponding nucleotide 
sequences. Selected genes and corresponding primer sequences are 
presented in paper III. 
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Polymerase chain reaction and Sanger sequencing 
In order to get optimal sequences, each PCR reaction were opti-
mized and unique PCR protocols were established for each gene 
(paper III). All PCR products were purified (paper III) and subject-
ed to cycle sequencing in both directions using BigDye Terminator 
v 3.1. All samples were analysed with Sanger sequencing using the 
ABI Prism 3130 genetic analyser (Applied Biosystems, CA, USA). 
Sanger sequencing is described in Figure 10. The sequences were 
edited and aligned as described in paper III. 
Table 4 Anaplasmataceae strains used for alignments and primer design  
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Results and discussion 
In this paper we wanted to study the genetic relationship between 
strains of Ca. N. mikurensis that had caused infection in humans, 
as well as determine the phylogenetic relationship between other 
members of the family of Anaplasmataceae and this new agent. All 
12 patients in this study were immune suppressed due to underly-
ing diseases (hematologic, rheumatologic) and immune suppressive 
Figure 10 Sanger sequencing technology. 1) Extracted DNA, where the region of 
interest is amplified by PCR (2). The PCR-product is cleaned up and subjected to 
cycle sequencing (3) where incorporation of fluorescent dideoxynucleotides 
(ddNTP) occurs. This product is then cleaned up to remove excess primers and 
unincorporated nucleotides before it is loaded on an automated DNA-sequencing 
instrument for electrokinetic separation (4) where a laser reads the sequence and 
detects the fluorescent intensity that is translated into a “peak” and several peaks 
creates a sequence (5). 
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therapy, i.e., rituximab or methotrexate. Three of nine Swedish pa-
tients were described in paper III (the rest were described in paper 
I) and the geographic location of all Swedish patients is shown in 
Figure 1, paper III.  
 
Unweighted pair group method with arithmetic mean (UPGMA) 
was constructed individually for each gene. This showed overall 
low genetic diversity among the clinical isolates. There were only 
two deviations, one nucleotide exchange in the lipA gene at posi-
tion 114 (T instead of C) seen in clinical isolates from three pa-
tients (SE01, SE02 and SE09) and one nucleotide substitution in 
the clpB locus (G instead of C) in a strain from one of the Czech 
patients, CZ01 (Figure 2 and 3, paper III). The nucleotide exchange 
in clpB locus was non-synonymous and resulted in an amino acid 
change of valine for leucine in position 421; of noteis that E. rumi-
nantium also has a leucine in this position (paper III). 
 
These results revealed three sequence types among the European 
clinical Ca. N. mikurensis isolates, one recovered in the western 
part of Sweden (with lipA exchange), one from central Europe 
(CZ1, with clpB exhange), and a  pan-European genotype (with 
identical sequences in both genes). Loewenich et al. had previously 
reported sequence variations in the groEl and 16S rRNA genes 
among Ca. N mikurensis isolates from different kinds of hosts 
(ticks, rodents, dog and human) but this might reflect bacterial ad-
aptation to survive in different host species
129
. However, Li et al. 
reported that different gene clusters were found in the same rodent 
species from different regions in China, which suggests that the 
genetic diversity might not be associated with different host spe-
cies, at least not among Chinese strains
118
. The same authors also 
reported genetic differences between strains infecting humans in 
China and Europe, respectively, with regard to sequences of the 
groEl and the rrs genes
118
. The main vector of Ca. N. mikurenis in 
Europe is I. ricinus, whereas in China it is I. persculcatus that is 
the main tick species
158
, which might explain the different se-
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quence variants. The Chinese variant of neoehrlichiosis also seems 
to differ from the European one, since infected immune competent 
individuals in China appear to have more systemic inflammation 
with prominent fever than has been seen among European immune 
competent patients
111
.  
 
The MLSA scheme we developed for Ca. N. mikurensis was able 
to distinguish between Ca. N. mikurensis and other species in the 
family of Anaplasmataceae. We were at this point rather surprised 
that E. ruminantium was a closer relative to our agent than was A. 
phagocytophilum (Fig 4, paper III). E. ruminantium has so far not 
been found to cause infection in humans but is the agent of heart-
water in domestic ruminants
75
. Today, when we know that Ca. N. 
mikurensis is capable of infecting endothelial cells, which is also 
the main target cell for E. ruminantium infection, this finding is not 
surprising
93
. 
 
This study has several limitations. The main challenge was to ex-
tract sufficiently high concentrations of Ca. N. mikurensis DNA 
from limited EDTA-blood volumes (collected before the patients 
were treated with doxycycline). The patients were selected because 
of their high loads of bacteria in their blood, which is needed for 
this type of DNA sequence-based analysis of multiple genes. The 
fact that all patients were immune suppressed and consequently 
had a more severe infection with higher amounts of bacteria, might 
have contributed to the low genetic diversity in this study. In this 
project it would have been interesting to compare the immune sup-
pressed patients with the healthy individuals that carry the bacteria 
to see if the same strains infect both patients groups. But, we were 
not able to perform MLSA on strains isolated from immune com-
petent persons because of insufficient amounts of bacterial DNA 
were recovered from them. 
 
Another limitation is that this MLSA scheme was constructed 
based on multilocus sequence typing (MLST) protocols developed 
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for related species, which may not have been the best genotyping 
markers for Ca. N. mikurensis. MLST is usually applied for inves-
tigate relationship between strains that belong to a well-defined 
species and normally involves 7 housekeeping genes, which is 
more preferable for epidemiologic purposes
159
.  
 
Our suggestion in this publication was to perform this MLSA ana-
lyse once we had managed to cultivate this uncultivatable species, 
to obtain higher amounts of bacterial DNA and thereby be able to 
optimize and sequence additional genes. By now, when we have 
succeed to perform whole-genome sequencing directly from clini-
cal samples (paper IV) we no longer believe this MLSA assay will 
contribute to any interesting findings. However, it was very inter-
esting to note that the results from the whole-genome sequencing 
had a very good concordance with the MLSA results as the Ca. N. 
mikurensis whole-genome sequenced strains also showed very lim-
ited genetic variation. 
Paper IV 
Candidatus Neoehrlichia mikurensis isolates 
EDTA-blood samples from three immune suppressed patients di-
agnosed with neoehrlichios were used for this study. Clinical data 
regarding these patients have been published before
93
. The embryo-
derived tick-cell line IRE/CTVM20 (obtained from I. ricinus) was 
inoculated with whole-blood from a diagnosed patient (SE18) to 
establish a culture of this agent. The tick-cell line was incubated 
for 21 weeks and continuously monitored by PCR and image 
stream analysis to control the infection stage
93
. 
 
To be able to perform whole-genome sequencing, high-molecular 
weight DNA was extracted using the MagAttract HMW DNA Kit 
(Qiagen, Hilden, Germany) described in paper IV. DNA yields and 
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purity were measured with Tape Station (Agilent Technologies, 
Santa Clara, California, USA) before proceeding to the 10X in-
strument. 
10X Chromium technique 
 
 
 
 
 
 
 
10X Chromium is a rather new microfluidic technology that has 
been developed to allow analysis of small amounts of input DNA, 
1 ng of high molecular weight (HMW) genomic DNA is sufficient. 
Each input DNA fragment is incorporated into an individual gel-
bead in emulsion (GEM), and subsequent biochemistry generates 
mini-libraries of NGS-ready molecules tagged with a barcode 
unique for each GEM (Fig 11)
160
. Barcode-tagged DNA molecules 
are released from each droplet and library preparation process is 
Figure 11 Overview of 10X Chromium technology. A) Gel beads loaded with primers 
labelled with unique barcodes are mixed inside an oil-droplet (GEM) with HMW DNA 
and enzymes. B) All GEMs are amplified and the droplets are dissolved and the prod-
ucts are purified and library is constructed and Illumina adapters are incorporated. The 
samples are then sequenced with Illumina technology (in this case Illumina HighSeq-
X). C) Each line represents linked-reads with the same barcode. Picture is adapted 
from Zheng G. et.al. [161] 
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performed. The resulting libraries then undergo standard Illumina 
short-read sequencing. A computational algorithm (Supernova as-
sembler) uses the barcodes to link sequencing reads back to the 
original HMW DNA molecule
160
. The workflow for the technique 
is described in Figure 11
161
. 
Illumina sequencing technique 
Illumina NGS workflows include four basic steps: 
 
1.   Library preparation: in this case, pooling of droplets, end-
repair, and ligation of P7 sequencing adaptor. These adap-
tors have flow cell binding sites, which allow the library 
fragment to attach to the flow cell surface (the Illumina flow 
cell is the where the sequencing chemistry occurs)
162
. 
 
2.   Cluster generation: the library is loaded into a flow cell and 
the fragments are hybridized to the flow cell surface. Each 
bound fragment is amplified in to a clonal cluster through 
bridge amplification. When cluster generation is complete, 
the templates are ready for sequencing
162
. 
 
3.   Sequencing: the clusters in the flow cell are read one nucleo-
tide at a time in repetitive cycles. During these cycles, fluo-
rescently labelled dNTPs are incorporated into the growing 
DNA chain
162
. 
 
4.   Data Analysis: in this study there were no reference se-
quences available for alignments. De novo sequencing refers 
to the sequencing of a novel genome where there is no refer-
ence sequence. The assembly of the genome and annotated 
genes is described in paper IV. 
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Results and discussion 
The goal with this paper was to perform de novo whole-genome 
sequencing of Ca. N. mikurensis. These in order to gain new 
knowledge about the bacterium and maybe identify target mole-
cules that can be used as diagnostic tools for this agent, and also 
acquire better understanding of its pathogenic mechanisms. 
 
Surprisingly, no sequencing data were obtained from the tick-cell 
line cultures. The cultures we used were from one of the first at-
tempts in culturing this agent and now, when we have gained more 
knowledge, we believe these cultures were harvested too late. The 
cell lines were heavily infected by the bacteria, which had probably 
started to undergo degradation. Our hypothesis had been that se-
quencing from cultures might be an advantage to achieve a higher 
amount of bacterial DNA, which had been the limitation in earlier 
whole-genome sequencing attempts of this agent. However, it is 
possible that the bacterium has host-specific attributes so that its 
virulence changes depending on the host
163
. Since, the culturing 
into tick-cell lines take more than 20 weeks for the infection to be 
established some genetic changes that enhance adaptation to a new 
host are likely to occur
93,164
. With these thoughts in mind it is better 
to sequence the bacteria directly from the infected human host if 
we want to study pathogenomics associated with severe complica-
tions in humans. 
 
The sequencing of the clinical isolates from patient plasma was 
successful, despite their low contents of bacterial DNA after se-
quencing. The samples only contained 0.1 to 5.1% bacterial DNA 
sequences (the rest was human). The highest amount of bacterial 
DNA was enriched from the first sample obtained from patient 
SE24, which probably depended on the fact that the DNA was ex-
tracted from fresh plasma (the other plasma samples had been 
stored frozen before extraction). The successful sequencing out-
come when using human plasma directly may depend on the fact 
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that contamination of the bacterial DNA with human DNA is ad-
vantageous when using 10X technology. The human DNA frag-
ments are larger than the bacterial DNA fragment, allowing for the 
later to “hitchhike” on the larger DNA human fragment, which ap-
parently protects and enhances the recovery and integrity of the 
bacterial DNA.  
 
All sequenced patients in this study were immune suppressed. The 
immune suppressed patients have (as we know so far) the highest 
concentrations of bacteria in their blood and were therefore select-
ed for this study. Patient SE24 (designated reference genome for 
Ca. N. mikurensis) had a high bacterial burden of 5.8 × 10
8
 gene 
copies/mL blood (Paper IV, table 1). Now, when we became edu-
cated in how to sequence directly from clinical samples it would be 
interesting to perform whole-genome sequencing of strains isolated 
from immune competent individuals. Even if we are unlikely to 
obtain the entire whole-genome sequence from immune competent 
patients (depending on their lower bacterial burden), we now have 
a reference genome to compare sequence data with. It will now al-
so be possible to study selected genes that could be involved in the 
pathogenesis of this agent.   
 
The size of the genome of Ca. N. mikurensis was estimated to be 
1.1 mbp and was found to contain 886 coding sequence (CDS) an-
notations, 924 gene annotations, including all six MLSA-genes, 36 
tRNAs, as well as a single copy each of the genes encoding 5S 
rRNA, 16S rRNA and, 23S rRNA, respectively. Similar to previ-
ously sequenced members of the order Rickettsiales Ca. N. miku-
rensis has a single rRNA operon and the 16S rRNA gene is 
separated from the 23S-5S gene pair by 426 kb
84
. It is more com-
mon for bacteria to have several rRNA operons and it is has been 
proposed that the number of rRNA operons may contribute to the 
rapidity with which microbes can synthesize ribosomes and re-
spond to changes in growth conditions
165,166
. It is also assumed that 
multiple copies of rRNA operons in prokaryotic organisms are re-
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quired to achieve high growth rates and this can explain way it 
takes a long time to establish Ca. N. mikurensis infection in cell 
cultures, as well as the long incubation period of neoehrlichiosis in 
patients
166
.  
 
The locations of the previously identified MLSA genes are visual-
ized in Figure 2 paper IV, and the characteristics of the Ca. N. 
mikurensis SE24 reference genome is summarized in Table 2, pa-
per IV. Ca. N. mikurensis has one of the smallest genomes in the 
family Anaplasmataceae and similar to several members in the 
family it also has numerous repeats in the genome. So far, we have 
identified that Ca. N. mikurensis harbours three repetitive gene 
families (Table 3, paper IV). The expansion of the outer membrane 
protein (OMP) family we have identified, is also found by close 
relatives to Ca. N. mikurensis and may contribute to the cross-
reactive antibodies to Anaplasma phagocytophilum
24
. Outer mem-
brane proteins are a common theme among pathogenic bacteria, 
thought to be of importance for bacterial interactions with eukary-
otic hosts. OMPs have a large repertoire of functions, including 
bacterial invasion, transportation of various molecules, adhesion of 
the bacteria to the host cell and signalling pathways
167
.  
 
Studies of the surface proteins of Ca. N. mikurensis will likely in-
crease our understanding of the interaction of bacteria with their 
host cells. A very promising finding is that we have identified a 
surface antigen that seems to be specific for Ca. N. mikurensis (po-
sition 577689-578213) that could be a candidate antigen for the 
development of Ca. N. mikurensis-specific serological assays. If 
we are able to design an enzyme-linked immunosorbent assay 
(ELISA) with this surface antigen, we can easily study larger popu-
lations of humans and increase our knowledge regarding the preva-
lence of exposure of various groups of healthy individuals and 
patients to this emerging pathogen in different areas of Sweden. 
We might also be able to produce monoclonal antibodies to this 
surface antigen, which could prove to be a valuable tool for future 
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studies of the disease mechanisms and immune defences that are 
operative in neoehrlichiosis. 
 
In this study we sequenced clinical isolates from three patients with 
neoehrlichiosis and the geographic origin of these patients are 
shown in Figure 1, paper IV. The genetic variation between the 
strains was very low, SE26 differed by 245 single-nucleotide vari-
ants (SNV) from SE24, and SE20 differed by 153 SNV from the 
SE24 reference. These findings support the results from the MLSA 
study that revealed an overall low genetic diversity among clinical 
isolates in Europe based on sequencing of six housekeeping genes 
(paper III). It would be interesting to whole-genome sequence all 
clinical strains that we have collected during the years (both Swe-
dish and European) to see if the genetic variations are consistently 
low for this agent, and to determine the number of genotypes that 
exist. In addition, it would be of interest to sequence strains col-
lected from diverse hosts to evaluate if there are genomic varia-
tions of Ca. N. mikurensis in different hosts.  
 
This work will hopefully advance our understanding of the patho-
genic mechanisms used by this emerging pathogen and also con-
tribute to the development of new diagnostic assays to facilitate 
and improve the ability to diagnose patient suffering from neoehr-
lichiosis. A broader arsenal of diagnostic tools may contribute to 
identify patients with other clinical pictures and with distinct risk 
factors from those that are known at present. 
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Concluding remarks and future 
perspectives 
The papers included in this thesis have contributed to a lot of new 
knowledge about this new human pathogen. In paper I we were 
able to describe this new infectious disease, termed neoehrlichiosis 
when we summarised new and earlier published cases regarding 
host factors, clinical picture, and laboratory findings. I think that 
this publication has been of great value to spread information of 
neoehrlichiosis and surely contributed to finding of new patients. 
 
At the beginning we thought that neoehrlichiosis only caused infec-
tions in immune suppressed patients but the study described in pa-
per II showed that immune competent patients can also become 
infected even if the symptoms are milder than those of immune 
suppressed patients.  
 
Paper III was the firsts paper published where more than three 
genes of Ca. N. mikurensis were analysed regarding genetic diver-
sity. Even if the method used in this paper has its limitations, espe-
cially now when we have succeed in sequencing the entire genome 
of Ca. N. mikurensis, the results in this publication have been sup-
ported by the whole-genome results. 
 
The last work in this thesis, paper IV, will hopefully contribute to a 
lot of new knowledge about this agent and the genetics involved in 
causing severe infection in many patients. The results from this pa-
per may also contribute to the development of new diagnostic tools 
that may prove to be of great value for diagnosing future patients. 
 
The journey with discovering and characterizing a new human 
pathogen is fascinating and challenging. From the start, when we 
diagnosed one of the first human neoehrlichiosis patients in the 
world, to developing clinical assays that up to date have diagnosed 
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39 Swedish patients (paper II) makes me proud. Many of the pa-
tients that we have diagnosed during these studies have been in re-
ally bad condition as a result of the infection and most of them 
have recovered completely when they finally got their diagnosis 
and could receive the correct treatment. The main goal with this 
thesis has been to spread the word about this new infectious disease 
and we have managed to take a step in right direction. The work 
does not end here; we have a lot of more questions to answer and 
an inexhaustible hunger for knowledge regarding (Candidatus) 
Neoehrlichia mikurensis! 
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